GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Forward PE Ratio

Antibe Therapeutics (TSX:ATE) Forward PE Ratio : 0.00 (As of May. 27, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Forward PE Ratio?

Antibe Therapeutics's Forward PE Ratio for today is 0.00.

Antibe Therapeutics's PE Ratio without NRI for today is 0.00.

Antibe Therapeutics's PE Ratio for today is 0.00.


Antibe Therapeutics Forward PE Ratio Historical Data

The historical data trend for Antibe Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Forward PE Ratio Chart

Antibe Therapeutics Annual Data
Trend 2020-05 2024-02
Forward PE Ratio
76.92 1.94

Antibe Therapeutics Quarterly Data
Forward PE Ratio

Competitive Comparison of Antibe Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, Antibe Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antibe Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Forward PE Ratio falls into.



Antibe Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Antibe Therapeutics  (TSX:ATE) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Antibe Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibe Therapeutics (TSX:ATE) Business Description

Traded in Other Exchanges
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
Executives
Daniel Marcel Legault Senior Officer
Alain Wilson Senior Officer
John Lawrence Wallace Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines